平消胶囊联合卡培他滨治疗晚期乳腺癌的临床研究

目的探究平消胶囊联合卡培他滨片治疗晚期乳腺癌的的临床疗效。方法选取2014年12月—2017年12月在川北医学院附属医院治疗的98例晚期乳腺癌患者作为研究对象,将所有患者根据随机数字表法分为对照组和治疗组,每组各49例。对照组患者口服卡培他滨片1.25 g/m~2,2次/d,连续服用2周后停药1周;治疗组在对照组的基础上口服平消胶囊,6粒/次,3次/d。3周为1个疗程,两组患者均连续治疗2个疗程。观察两组患者的临床疗效,同时比较两组治疗前后的免疫学指标、肿瘤标志物水平、KPS评分、无进展生存期(PFS)、总体生存期(OS)。结果治疗后,对照组和治疗组患者的客观缓解率分别为22.45%、48.98%,疾病控制率分别为63.27%、85.71%,两组比较差异有统计学意义(P0.05)。治疗后,对照组CD3~+、CD4~+、CD4~+/CD8~+水平均明显降低,治疗组CD3~+、CD4~+、CD4~+/CD8~+水平均明显升高,(P0.05);治疗后,治疗组免疫学指标水平显著高于对照组(P0.05)。治疗后,两组患者癌胚抗原(CEA)和血管内皮生长因子(VEGF)水平均明显降低(P0.05);治疗后,治疗组血清肿瘤标志物水平显著低于对照组(P0.05)。治疗后,两组患者KPS评分均显著升高(P0.05);治疗后,治疗组KPS评分显著高于对照组(P0.05)。治疗后,治疗组患者PFS和OS均显著高于对照组,两组比较差异具有统计学意义(P0.05)。结论平消胶囊联合卡培他滨片治疗晚期乳腺癌具有较好的临床疗效,可以减轻化疗不良反应,提高机体免疫水平,延长患者生存期,具有一定的临床推广应用价值。

Clinical study on Pingxiao Capsules combined with capecitabine in treatment of advanced breast cancer

Objective To investigate the clinical efficacy of Pingxiao Capsules combined with Capecitabine Tablets in treatment of advanced breast cancer. Methods Patients (98 cases) with advanced breast cancer in Affiliated Hospital of North Sichuan Medical College from December 2014 to December 2017 were randomly divided into control and treatment groups, and each group had 49 cases. Patients in the control group were po administered with Capecitabine Tablets 1.25 g/m², twice daily for two weeks and then stopped it for one week. Patients in the treatment group were po administered with Pingxiao Capsules on the basis of control group, 6 grains/time, three times daily. A course of treatment had three weeks, and patients in two groups were treated for two courses. After treatment, the clinical efficacy was evaluated, and the immunological indicator, serum tumor marker levels, KPS score, PFS, and OS in two groups before and after treatment were compared. Results After treatment, the objective remission rates in the control and treatment groups were 22.45% and 48.98%, respectively, and the disease control rates in the control and treatment groups were 63.27% and 85.71%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the control group were significantly decreased, but the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the treatment group were significantly increased (P<0.05). After treatment, the immunological indicator levels in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the levels of CEA and VEGF in two groups were significantly decreased (P<0.05). After treatment, serum tumor marker levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the KPS scores in two groups were significantly increased (P<0.05). After treatment, KPS scores in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the PFS and OS in the treatment group were significantly longer than those in the control group, with significant difference between two groups (P<0.05). Conclusion Pingxiao Capsules combined with Capecitabine Tablets has a good clinical effect in treatment of advanced breast cancer, can alleviate the adverse reaction of chemotherapy, improve the immune level, and prolong the survival time of patients,, which has a certain clinical application value.